Atlas company financials

BIOGEN INC.

Standardized 19-year financial series for BIOGEN INC., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0000875045FY2007 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$9.9B

Adjusted EBITDA

—

Net result

$1.3B

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$2.5B

TTM revenue

$10.1B

TTM free cash flow

—

Latest quarter net result

$466.5M

Quarterly coverage: 53 periods · latest quarter FY2025-Q3 · TTM revenue growth 3.4%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · biogen-inc-fy2007 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2010-02-09 · Retrieved: 2026-04-26T11:43:04.396919+00:00
SEC EDGAR companyfacts
us-gaap:InterestExpense · us gaap companyfacts · comparative · biogen-inc-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-02-04 · Retrieved: 2026-04-26T11:43:04.396919+00:00
SEC EDGAR companyfacts
primary · biogen-inc-fy2011 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-03 · Retrieved: 2026-04-26T11:43:04.396919+00:00
SEC EDGAR companyfacts
primary · biogen-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-02-05 · Retrieved: 2026-04-26T11:43:04.396919+00:00
SEC EDGAR companyfacts
primary · biogen-inc-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-06 · Retrieved: 2026-04-26T11:43:04.396919+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2007	3B	—	780M	638M	1B	-284M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing total assets
FY2008	4B	—	1B	783M	2B	-276M	-595M	comparative annual fact carried from later 10k · missing adjusted ebitda · missing gross profit
FY2009	4B	—	1B	970M	1B	-166M	-562M	missing adjusted ebitda
FY2010	5B	—	1B	1B	2B	-173M	413M	missing adjusted ebitda
FY2011	5B	—	2B	1B	2B	-208M	512M	missing adjusted ebitda
FY2012	6B	—	2B	1B	2B	-255M	904M	missing adjusted ebitda
FY2013	7B	—	3B	2B	2B	-246M	-10M	missing adjusted ebitda · missing research and development
FY2014	10B	—	4B	3B	3B	-288M	-623M	missing adjusted ebitda · missing research and development
FY2015	11B	—	5B	4B	4B	-643M	5B	missing adjusted ebitda · missing research and development
FY2016	11B	—	5B	4B	5B	-616M	4B	missing adjusted ebitda · missing research and development

Filing provenance